Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | USP2 | O75604 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090559 | 0.88 | ACHE (0.37) | MAPK14CYP1A2CYP3A4ALDH1A1MEN1 | |
| SCHEMBL4090269 | 0.88 | ACHE (0.37) | MAPK14CYP1A2CYP3A4ALDH1A1MEN1 | |
| SCHEMBL4098900 | 0.87 | MAPK14 (0.36) | MAPK14ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL4094675 | 0.85 | MAPK1 (0.34) | MAPK14ALDH1A1KMT2ATP53MAPK1 | |
| SCHEMBL13708605 | 0.85 | MAPK1 (0.34) | MAPK14ALDH1A1KMT2ATP53MAPK1 | |
| SCHEMBL4095535 | 0.85 | ACHE (0.42) | MAPK14CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL4091458 | 0.85 | ACHE (0.42) | MAPK14CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL4098877 | 0.84 | CCNT1 (0.40) | MAPK14MAP3K12ADORA3ADORA2A | |
| SCHEMBL4084115 | 0.82 | MAP3K12 (0.38) | MAPK14MAP3K12SYK | |
| SCHEMBL13708533 | 0.82 | MAP3K12 (0.38) | MAPK14MAP3K12SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1727821-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
| WO-2005070934-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | MAPK14 1220/4885CYP1A2 2889/4885CYP3A4 1954/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | MAPK14 964/4885CYP1A2 2605/4885CYP3A4 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.